H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls
H.R.6383, Uterine Fibroid Research and Education Act of 2020
H.R.7647, To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage
340B drug discount program policy issues
Drug cost and pricing policy issues
Patient affordability issues
Policy proposals relating to clinical trial diversity
Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule H.R.5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
S.1416, Affordable Prescriptions for Patients Act of 2019
Patent litigation reform issues and issues related to post-grant proceedings at the USPTO
Value of intellectual property H.R. 133, Consolidated Appropriations Act, 2021 - Provisions relating to pharmaceuticals Policy proposals impacting biopharmaceutical supply chain
USITC 337 review H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions
S. 1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues
S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing
S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates
S. 3129, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions
Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First
Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen
Policy Proposals related to Medicare Part D and patient cost-sharing
Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues
Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (CMS 2482-F)
CMS Most Favored Nation (MFN) Model interim final rule (MFN Rule), implementing President Trump's proposal to align drug prices in the United States with those available in economically similar countries Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation 
Policy proposals relating to economic activity in Puerto Rico
International tax issues, including OECD digital taxation work program
HCR - Health Issues CPT - Copyright/Patent/Trademark BUD - Budget/Appropriations TRD - Trade (domestic/foreign) MMM - Medicare/Medicaid TAX - Taxation/Internal Revenue Code
24 - Commerce, Dept of (DOC) 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 1 - SENATE 41 - Treasury, Dept of 22 - U.S. Trade Representative (USTR) 24 - Commerce, Dept of (DOC) 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 1 - SENATE 41 - Treasury, Dept of 22 - U.S. Trade Representative (USTR) 24 - Commerce, Dept of (DOC) 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 1 - SENATE 41 - Treasury, Dept of 22 - U.S. Trade Representative (USTR) 24 - Commerce, Dept of (DOC) 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 1 - SENATE 41 - Treasury, Dept of 22 - U.S. Trade Representative (USTR) 24 - Commerce, Dept of (DOC) 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 1 - SENATE 41 - Treasury, Dept of 22 - U.S. Trade Representative (USTR) 24 - Commerce, Dept of (DOC) 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 1 - SENATE 41 - Treasury, Dept of 22 - U.S. Trade Representative (USTR)
ABBVIE, INC.
1399 New York Avenue NW, Suite 600, Washington, DC, 20005, US
STEPHEN SCANGO DANIEL BACHNER BINTA BEARD DANIEL BACHNER STEPHEN SCANGO BINTA BEARD DORCAS ADEKUNLE (Legislative Assistant (1/2015-9/2015), Senior Counsel (9/2015-5/2017) and Chief Counsel (5/2017-12/2018) for Representative Bonnie Watson Coleman; Legislative Director and Deputy Chief of Staff (1/2019-11/2020) for Representative Susan Wild) DANIEL BACHNER STEPHEN SCANGO BINTA BEARD DANIEL BACHNER STEPHEN SCANGO STEPHEN SCANGO DANIEL BACHNER BINTA BEARD DANIEL BACHNER STEPHEN SCANGO DORCAS ADEKUNLE (Legislative Assistant (1/2015-9/2015), Senior Counsel (9/2015-5/2017) and Chief Counsel (5/2017-12/2018) for Representative Bonnie Watson Coleman; Legislative Director and Deputy Chief of Staff (1/2019-11/2020) for Representative Susan Wild)
Legislative Assistant (1/2015-9/2015), Senior Counsel (9/2015-5/2017) and Chief Counsel (5/2017-12/2018) for Representative Bonnie Watson Coleman; Legislative Director and Deputy Chief of Staff (1/2019-11/2020) for Representative Susan Wild Legislative Assistant (1/2015-9/2015), Senior Counsel (9/2015-5/2017) and Chief Counsel (5/2017-12/2018) for Representative Bonnie Watson Coleman; Legislative Director and Deputy Chief of Staff (1/2019-11/2020) for Representative Susan Wild